CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions
Primary Purpose
Laryngeal Disease, Laryngeal Tumor, Laryngopharyngeal Reflux
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Endo CDx Brush biopsy
Sponsored by
About this trial
This is an interventional screening trial for Laryngeal Disease focused on measuring Larynx, reflux, LPR, tumor, lesion
Eligibility Criteria
Inclusion Criteria:
- Age 18 or over
- patients suspected to suffer from LPR
- Patients with laryngeal/hypopharyngeal lesions.
Exclusion Criteria:
- Patient refusal
- Patients with anatomical variants which precludes biopsy taking.
- Patients with allergy to lidocain-based local anesthesia agents.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Brush biopsy for laryngeal lesion
Brush biopsy for LPR
Arm Description
Brush biopsy of the larynx - in addition to the standard biopsy
Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)
Outcomes
Primary Outcome Measures
Efficacy of EndoCDx brush
Efficacy of EndoCDx brush biopsy as a diagnostic tool for laryngeal lesions compared to cup forceps biopsy and a diagnostic tool for LPR compared to double probe PH monitoring
Secondary Outcome Measures
Assessment of pain
Assessment of pain during EndoCDx brush biopsy under local anesthesia by Visual Analog Score for pain
Full Information
NCT ID
NCT03214835
First Posted
July 10, 2017
Last Updated
July 16, 2020
Sponsor
CDx Diagnostics
Collaborators
Rambam Health Care Campus
1. Study Identification
Unique Protocol Identification Number
NCT03214835
Brief Title
CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions
Official Title
CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Withdrawn
Why Stopped
Study halted prematurely, prior to enrollment of first participant.
Study Start Date
February 1, 2018 (Anticipated)
Primary Completion Date
August 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CDx Diagnostics
Collaborators
Rambam Health Care Campus
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The study will take place at Rambam medical center, department of Otolaryngology Head and Neck Surgery, for two years. Patients suspected of LPR or laryngeal l tumor and are candidate for laryngeal or hypopharyngeal biopsies will be recruited.
Detailed Description
First- all patients visiting our clinic with laryngeal complaints suspicious for either LPR or laryngeal tumor will fill the RSI questionnaire. Then fiberoptic examination will be performed by a laryngologist that will complete the RFS score.
Patients with suspicious lesions will be referred for TFL standard biopsy and CDx brush biopsy in order to determine whether the lesions are malignant or benign. The pathologic diagnosis of invasive carcinoma from a TFL biopsy is considered equivalent to the pathology results from a direct laryngoscopy biopsy. All patients with benign pathology or carcinoma in-situ (CIS) on TFL biopsy will be referred for subsequent direct laryngoscopy (DL) for definitive diagnosis. At the time of the DL biopsy will include also another CDx brush smear. Patients with benign-appearing lesions will be taken for lesion removal and biopsy.Before removal of the lesion a CDx brush smear will be collected.
All the participants suspected of LPR will have: PHmetry with Manometry andCDx brush biopsy.All relevant demographic and clinical data will be retrieved for analysis.
CDx biopsies will be an addition to the routine management of the patients in the diagnosis and follow-up of laryngeal lesions and LPR and will not replace the standard regimen.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Laryngeal Disease, Laryngeal Tumor, Laryngopharyngeal Reflux
Keywords
Larynx, reflux, LPR, tumor, lesion
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Brush biopsy for laryngeal lesion
Arm Type
Experimental
Arm Description
Brush biopsy of the larynx - in addition to the standard biopsy
Arm Title
Brush biopsy for LPR
Arm Type
Experimental
Arm Description
Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)
Intervention Type
Device
Intervention Name(s)
Endo CDx Brush biopsy
Intervention Description
In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
Primary Outcome Measure Information:
Title
Efficacy of EndoCDx brush
Description
Efficacy of EndoCDx brush biopsy as a diagnostic tool for laryngeal lesions compared to cup forceps biopsy and a diagnostic tool for LPR compared to double probe PH monitoring
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Assessment of pain
Description
Assessment of pain during EndoCDx brush biopsy under local anesthesia by Visual Analog Score for pain
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 or over
patients suspected to suffer from LPR
Patients with laryngeal/hypopharyngeal lesions.
Exclusion Criteria:
Patient refusal
Patients with anatomical variants which precludes biopsy taking.
Patients with allergy to lidocain-based local anesthesia agents.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jacob Cohen, MD
Organizational Affiliation
Rambam Health Care Campus
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions
We'll reach out to this number within 24 hrs